Research Analysts Offer Predictions for Hologic Q2 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for Hologic in a report issued on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now anticipates that the medical equipment provider will post earnings of $1.06 per share for the quarter, up from their prior forecast of $1.04. The consensus estimate for Hologic’s current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Hologic’s Q4 2025 earnings at $1.11 EPS and FY2025 earnings at $4.27 EPS.

Several other equities research analysts have also issued reports on HOLX. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday. Leerink Partners decreased their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Royal Bank of Canada raised their price objective on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday. Finally, Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $89.25.

Hologic Price Performance

NASDAQ HOLX opened at $79.29 on Thursday. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $18.42 billion, a PE ratio of 23.81, a price-to-earnings-growth ratio of 3.03 and a beta of 0.98. Hologic has a 12-month low of $66.93 and a 12-month high of $84.67. The company has a 50 day moving average price of $81.02 and a two-hundred day moving average price of $78.13.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 20.11% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the company earned $0.89 EPS. The firm’s revenue was up 4.5% on a year-over-year basis.

Institutional Investors Weigh In On Hologic

Hedge funds and other institutional investors have recently modified their holdings of the stock. Innealta Capital LLC bought a new stake in Hologic in the 2nd quarter valued at $25,000. Wolff Wiese Magana LLC bought a new position in shares of Hologic during the 3rd quarter worth about $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic during the first quarter valued at about $37,000. Sunbelt Securities Inc. bought a new stake in shares of Hologic in the second quarter valued at about $37,000. Finally, Cromwell Holdings LLC grew its position in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 416 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.